Cinnamon Shows Potential As Tool in Fight Against Obesity

This article originally appeared here.
Share this content:
Cinnamon Shows Potential As Tool in Fight Against Obesity
Cinnamon Shows Potential As Tool in Fight Against Obesity

MONDAY, Nov. 27, 2017 (HealthDay News) -- The compound cinnamaldehyde (CA), found in cinnamon, activates fat cells to start burning energy in both mice and humans, according to a study published in the December issue of Metabolism.

Juan Jiang, from the University of Michigan in Ann Arbor, and colleagues used a mouse model assessing the cell-autonomous response of primary adipocytes to CA treatment. Additionally, human adipose stem cells were differentiated and treated with CA to assess whether the CA-mediated signaling was present in humans, too.

The researchers found that in murine primary adipocytes, CA significantly activated PKA signaling, increased expression levels of thermogenic genes, and induced phosphorylation of hormone-sensitive lipase and protein perilipin 1. The CA-induced thermogenic response was inhibited with inhibition of PKA or p38 MAPK enzymatic activity. Chronic CA treatment was found to regulate metabolic reprogramming, which was partially diminished in FGF21KO adipocytes. Both acute and chronic effects of CA were seen in human adipose stem cells, which were isolated from donors of different ethnicities, ages, and a variety of body mass indexes.

"Given the wide usage of cinnamon in the food industry, the notion that this popular food additive, instead of a drug, may activate thermogenesis, could ultimately lead to therapeutic strategies against obesity that are much better adhered to by participants," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »